

Impact of Pharmacovigilance in world

Panshika Sonkhla*

Department of Biotechnology, SUSCET Mohali, Punjab

*Corresponding author: Panshika Sonkhla, Department of Biotechnology, SUSCET Mohali, Punjab, Tel: 7508321664; E-Mail: Panshikasonkhla93@gmail.com

Received: February 04, 2017; Accepted: February 21, 2017; Published: February 28, 2017

Abstract

Pharmacovigilance resembles a sunshade to portray the procedures for checking and assessing ADRs and it is a key segment of successful medication direction frameworks, clinical practice and general well-being programs. The quantity of Adverse Drug Reactions (ADRs) reported brought about an expansion in the volume of information took care of, and to comprehend the pharmacovigilance, an abnormal state of skill is required to quickly recognize medicate chances and also to shield the item against a wrong expulsion. The current worldwide system of pharmacovigilance focuses, facilitated by the Uppsala Monitoring Centre, would be reinforced by an autonomous arrangement of audit. This would consider belligerent and essential medication security issues that can possibly influence general wellbeing unfavorably past national limits. As of late, pharmacovigilance has been limited, mostly to distinguish unfavorable medication occasions that were already either obscure or inadequately caught on. Pharmacovigilance is a critical and essential piece of clinical research and nowadays it is developing in numerous nations. Today numerous pharmacovigilance focuses are working for medication wellbeing observing in this worldwide pitch, in any case, at the turn of the thousand years pharmacovigilance confronts significant difficulties in part of better security and checking of medicines. In this survey we will talk about medication security, overall pharmacovigilance focuses and their part, advantages and difficulties of pharmacovigilance and its future thought in social insurance segments.

keywords: Drug safety; Adverse Drug Reactions; Pharmacovigilance

Introduction

Pharmacovigilance (PV), additionally called drug safety, is that the medical specialty science about the gathering, detection, assessment, monitoring, and interference of adverse effects with pharmaceutical merchandise [1].

The history roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to stay watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, that square measure outlined as any response to a drug that is noxious and inadvertent, together with lack of effectiveness (the condition that this definition solely applies with the doses commonly used for the prevention, designation or medical aid of illness, or for the modification of physiological disorder operate was excluded with the newest change of the applicable legislation [2-4]. Medication errors like o.d., and misuse and abuse of a drug also as drug exposure throughout gestation and breastfeeding, are of interest, even while not associate adverse event, as a result of they will lead to associate adverse drug reaction [5-6].

Information received from patients and attention suppliers via pharmacovigilance agreements, in addition as different sources like the medical literature, plays an important role in providing the info necessary for pharmacovigilance to require place. In fact, so as to plug or to check a pharmaceutical product in most countries, adverse event information received by the license holder (usually a pharmaceutical company) should be submitted to the native drug administrative body [7-9].

Ultimately, pharmacovigilance thinks about with distinctive the hazards related to pharmaceutical merchandise and with minimizing the danger of any heart that will come back to patients. Corporations should conduct a comprehensive drug safety and pharmacovigilance audit to assess their compliance with worldwide laws, rules, and steering [10-11].

8th Global Pharmacovigilance & Drug Safety conference was held on 10th July & 11th July 2017 at Jakarta, Indonesia where they discuss about the significance & scope of pharmacovigilance. The main aim of pharmacovigilance is to supply complete and clear info associated with drug safety and numerous risks and advantages related to them. Pharmacovigilance will facilitate in providing info of accidental and severe adverse events that couldn't be provided by clinical trials involving in-vivo methodology [12,13]. It enhances the impact of pharmacovigilance on patient welfare and public health and to grasp about pharmacovigilance. This track offers a quick discussion on Pharmacovigilance role in tending system [46]. Pharmacovigilance plays an important the role in healthcare system. There are so many laws and rules which are followed in pharmacovigilance practice. The Role of drug industries is to maintain the system and data of pharmacovigilance system. And the main scope is to deal with Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines [14-16].

9th International Pharmacovigilance & Drug Safety Conference and Exhibition was held on July 17-19, 2017 at Munich, Germany where they discuss about the importance and purpose of pharmacovigilance. In this, they discuss the improvement of patient safety and enhance the care in term of utilization of medicine [17,18]. And it helps to reduce the side effects of medicine. Its main purpose is to provide the clinical training in pharmacovigilance and increase the awareness about the pharmacovigilance in public [19,20].

10th Pharmacovigilance Congress was held on Sep 21-22, 2017 Charlotte, USA where they discuss about the clinical and pre-clinical trials. In clinical trials improve the quality of drug and development of new medicinal product by new techniques. In pre-clinical trials, the drug safety data are collected and it is done before the clinical trials [21,22].

The International Society of Pharmacovigilance (ISoP) is a non-profitable and independent society. The main goal of this society is to provide safe and effective drugs. This society main aim is that every country should learn about the pharmacovigilance [23,24]. In the view of ISOP the scope of pharmacovigilance is very wide. This society help to reduce the problems related to the medicine. The pharmacovigilance enhance the patient care and patient safety in relation to the use of medicines [25-27].

The World health Organization (WHO)

The WHO was established its program in 1961 related to the pharmacovigilance and drug safety. The principle of international collaboration within the field of pharmacovigilance is that the WHO International Drug observation Programme has 100 member nations in system and that members should record and report adverse effects of medication in their patients reports [28,29]. Member countries send their reports to the metropolis observation Centre where they are processed evaluated and entered into the WHO International Database, through membership within the WHO Programme one country will apprehend if similar reports area being created elsewhere then the area unit may reports of adverse reactions to a selected drug [30,31].

The International Council Of harmonization (ICH)

US, pharmaceutical research and manufacture of America (PRMA), European free trade Association (EFTA). And the main aim of this organization is to set the standard of drug companies around the world [32-34].

The Council for International Organizations of Medical Science (CIOMS) this organization is collaborated with World Health Organization (WHO) and the organisation has main aim is to provide the guide lines on drug safety [35]. This organization has evaluated the data and prepares the reports on the drug safety, further they use these reports as a reference on the development of drug regulatory policy. This Organization has adopted many policies related to the drug safety [36-38].

The Uppsala Monitoring centre (UMC) The central capacity of the Uppsala Monitoring Centre is to deal with the global database of ADR reports got from National Centres. The Uppsala Monitoring Centre has built up institutionalized reporting by every single National Centre and has encouraged correspondence between nations to advance quick recognizable proof of signs [39-41].

Materials and Methods Risk Assessments

It is that plan in pharmacovigilance which is responsible in signal detection and monitoring the files of risk benefits of drugs. These assessments have other keys which compile the reports of risk management plans (RMP) and maintain report as the periodic safety update report, periodic benefit-risk evaluation report and development safety update report [42-44].

Management of Causality

A standout amongst the most essential, and testing, issues in pharmacovigilance is that of the assurance of causality [45]. Causality alludes to the relationship of a given unfavorable occasion to a particular medication. Causality assurance (or appraisal) is frequently troublesome in light of the absence of obvious or solid information [46,47]. While one may expect that a positive fleeting relationship may "demonstrate" a positive causal relationship, this is not generally the situation [48,49]. For sure, a "honey bee sting" AE—where the AE can unmistakably be credited to a particular cause—is by a wide margin the special case as opposed to the run the show. This is because of the many-sided quality of human physiology and in addition that of ailment and ailments [50-52]. By this retribution, keeping in mind the end goal to decide causality between an unfavorable occasion and a medication, one should first reject the likelihood that there were other conceivable causes or contributing components [53,54]. On the off chance that the patient is on various pharmaceuticals, it might be the blend of these medications which causes the AE and no one exclusively. There have been various late prominent situations where the AE prompted to the demise of a person [55,56]. The individual were not overdosed with any of the numerous solutions they were taking, yet the mix there seemed to bring about the AE. Thus it is vital to incorporate into AE report, the medication being accounted for, as well as every single other medication the patient was additionally taking [57,58].

Detection of signals

Detection of signals includes a scope of strategies. The WHO characterizes a well-being signal as: "Reported data on a conceivable causal relationship between an unfriendly occasion and a medication, the relationship being obscure or deficiently archived beforehand". Normally more than a solitary report is required to produce a signal, contingent on the occasion and nature of the data accessible [59,60].

Information mining pharmacovigilance databases is one approach that has turned out to be progressively prevalent with the accessibility of broad information sources and reasonable figuring assets [61]. The information sources (databases) might be possessed by a pharmaceutical organization, a medication administrative power, or a huge medicinal services supplier. Individual Case Safety Reports (ICSRs) in these databases are recovered and changed over into organized organization, and factual strategies are connected to ascertain factual measures of affiliation [62,63]. On the off chance that the factual measure crosses a self-assertively set limit, a signal is proclaimed for a given medication connected with a given antagonistic occasion [64,65]. All signs regarded deserving of examination, require encourage investigation utilizing every single accessible data as a part or discredit the signal. In the event that the investigation is uncertain, extra information might be required, for example, a post-showcasing observational trial [66,67].

Risk & Benefit of drugs

Pharmaceutical organizations are required by law in many nations to perform clinical trials, testing new medications on individuals before they are made for the most accessible part [68,69]. This happens after a medication has been pre-screened for poisonous quality, once in a while utilizing creatures for testing. The makers or their operators normally select a delegate test of patients for whom the medication is outlined – at most a couple of thousand – alongside an equivalent control gather. The control gathering may get a fake treatment and additionally another medication, regularly an alleged "highest quality level" that is "ideal" medication showcased for the ailment [70-72].

The reason for clinical trials is to decide:

On the off chance that a medication works and how well it functions

On the off chance that it has any destructive impacts, and

On the off chance that it benefits more than damage and what amount more?

The factors in a clinical trial are determined and controlled, yet a clinical trial can never recount the entire story of the impacts of a medication in all circumstances [73,74]. Truth be told, nothing could recount to you the entire story, however a clinical trial must let you know; "sufficiently enough" being controlled by enactment and by contemporary judgements about the satisfactory adjust of advantage and damage [75,76].

Medical Devices

A medicinal gadget is an instrument, mechanical assembly, embeds, in vitro reagent, or comparative or related article that is utilized to analyze, avoid, or treat sickness or different conditions, and does not accomplish its motivations through concoction activity inside or on the body [77-79]. While therapeutic items (additionally called pharmaceuticals) accomplish their important activity by pharmacological, metabolic or immunological means, medicinal gadgets act by physical, mechanical, or warm means [80-82]. Restorative gadgets shift significantly in complexity nature and application. Illustrations extend from straight forward gadgets, for example, tongue depressors, restorative thermometers, and expendable gloves to cutting edge gadgets, for example, medicinal robots, cardiovascular pacemakers, and neuroprosthetics [83-85].

Related to Herbal medicine

The utilization of herbs as conventional solutions keeps on growing rapidly over the world; numerous people now take home grown medicine or home grown items for their social insurance in various national human services settings [86,87]. However, broad communications reports of unfriendly occasions with home grown medicine can be inadequate and along

these lines misleading [88,89]. Moreover, it can be hard to recognize the reasons for home grown prescription related antagonistic occasions since the measure of information on every occasion is for the most part not exactly for pharmaceuticals formally managed as medications [90,91].

Conclusion

Pharmacovigilance keeps on assuming an essential part in meeting the difficulties postured by the perpetually expanding extent and power of meds, all of which convey an inescapable and a few circumstances eccentric potential for damage [92,93]. At the point when antagonistic impacts and poisonous quality do show up, particularly when already obscure, it is fundamental that these are accounted for, examined and their note worthiness is conveyed viably to the group of on lookers having learning to translate the data [94,95]. For all drugs, there is an exchange off between the advantages and the potential for mischief. The mischief can be minimized by guaranteeing that solutions of good quality, well-being and viability are utilized objectively, and that the desires and worries of the patient are considered when remedial choices are made [96-98]. To accomplish this is to serve general wellbeing, and to encourage a feeling of trust among patients in the medications they utilize that would develop the trust in the wellbeing administration when all is said in done, guarantee that dangers in medication utilize are foreseen and oversaw, furnish controllers with the essential data to correct the suggestions on the utilization of the drugs, enhance correspondence between the wellbeing experts and the general population and instruct wellbeing experts to comprehend the viability or danger of meds that they endorse [99-102].

REFERENCES

1. Naik P. The Future of Pharmacovigilance. *J Pharmacovigilance*. 2015; 3:159.
2. Hale Zerrin Toklu. Pharmacovigilance of Herbal Medicine: Herbavigilance. *Adv Pharmacoepidemiol Drug Saf*. 2016; 5: 208.
3. Kaur I, Kalaiselvan V, Kumar R, Mishra, et al. Effective Reporting by Pharmacist in Pharmacovigilance Programme of India. *Adv Pharmacoepidemiol Drug Saf* 2015; 4: 197.
4. Lores-González JC, Moyano BS, Pérez-Guerrero JJ, et al. Effect of Previously Administered Medication on Length of Hospital Stay in Patients with Moderate Acute Bronchiolitis. *J Infect Dis Preve Med*. 2016; 4: 135.
5. Raschi E, Poluzzi E, Koci A, et al. Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database. *J Pharmacovigilance* 2013; 1: 104.
6. Prasad A, Datta PP, Bhattacharya J, et al. Pattern of Adverse Drug Reactions Due to Cancer Chemotherapy in a Tertiary Care Teaching Hospital in Eastern India. *J Pharmacovigilance*. 2013; 1: 107.
7. Richards NL, Hall SW, Harrison NM, et al. Merging Wildlife and Environmental Monitoring Approaches with Forensic Principles: Application of Unconventional and Non-Invasive Sampling in Eco-Pharmacovigilance. *J Forensic Res* 2014; 5: 228.
8. Wertheimer A. The Impact of Personalized Medicine on Pharmacovigilance. *J Pharmacovigilance*. 2015; 3: 133.
9. Allabi AC, Nwokike J. A Situational Analysis of Pharmacovigilance System in Republic of Benin. *J Pharmacovigilance*. 2014; 2: 136.
10. Magyar I, Botea M, Maghiar A, et al. The Rational Use of Mucolytic Drugs in Children: Worsening of the Cough as Adverse Drug Reaction after Carbocysteine in Children. *Clin Exp Pharmacol*. 2013; 3: 140.
11. Wahab IA, Pratt NL, Kalisch LM, et al. Sequence Symmetry Analysis and Disproportionality Analyses: What Percentage of Adverse Drug Reaction do they Signal?. *Adv Pharmacoepidemiol Drug Saf*. 2013; 2: 140.

12. Ortiz JAA. Pharmacovigilance Legal Requirements for Marketing Authorization Holders in Spain. *J Pharmacovigilance*. 2014; 2: 132.
13. Panda AK. Ayurveda Medication Non Adherence: Implications for Clinical Practice and Research. *J Tradi Med Clin Natur* 2016; 5: 123.
14. Brown JD, Hutchison LC, Martin BC. Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. *J Gerontol Geriatr Res*.2016; 5: 321.
15. Whitstock MT, Pearce CM, Eckermann EJ. Randomised Controlled Trials and ‘Unexpected’ Adverse Events Associated with Newly Released Drugs: Improvements in Pharmacovigilance Systems are Necessary for Real-Time Identification of Patient Safety Risks. *J Clinic Toxicol*.2011; 2:1.
16. Garlapati S. Pharmacoepidemiology & Pharmacovigilance: Pow-erful Emerging Areas to ConquerMore. *Adv Pharmacoepidem Drug Safety*.2012; 1: 110.
17. Gothwal SK, Khosya S, Gharpure N Dapsone. Hypersensitivity Syndrome- A Fatal Adverse Drug Reaction. *Intern Med*.2013; 3: 123.
18. Flower DR. Pharmacovigilance, Drug Repositioning, and Virtual Screening. *J Pharmacovigilance*.2013; 1:103.
19. Maldonado C, Vázquez M, Guevara N, et al. Use of STOPP/ START Criteria to Perform Active Pharmacovigilance in the Elderly .*J Pharmacovigilance*.2014;2:146.
20. Elhassan GO. Pharmacovigilance: Clinical Perspectives towards Patient Safety. *J Pharmacovigil*.2015; 3:129.
21. Edwards SG, Hartwell EE, Mooney L, et al. Changes in Stress Reactivity among Stimulant Dependent Adults After Treatment with Mindfulness Based Relapse Prevention: Results from a Pilot Randomized Clinical Trial. *J Addict Res Ther*.2016;7: 298.
22. Wang Z, Yuan A, TanMT. Computation of the Properties of Multi-Stage Clinical Trial Design Based on SCPRT.*J Clin Trials*.2016; 6: 274.
23. Vijay Kumar. Challenges and Future Consideration for Pharmacovigilance. *J Pharmacovigilance*. 2013; 1: 102.
24. Reis CD, Veiga CE, Martins JJ. Pharmacovigilance in Cabo Verde: Measuring the Awareness and Knowledge of Consumers. *J Pharmacovigil*.2016; 4: 200.
25. Tawde S. A Generic Pharmaceuticals: Is Pharmacovigilance Required?.*J Pharmacovigil*. 2014; 2: 124.
26. Montanari-Vergallo G. Recent Developments in EU and US Pharmacovigilance Legislation. *J Pharmacovigilance*.2013; 1: 105.
27. Magyar I. An Overview on the Third Annual Pharmacovigilance Forum. *Clin Pharmacol Biopharm*. 2015; 5: 122.
28. Swain S, Patra CN. Impact of Pharmacovigilance in Healthcare System: Regulatory Perspective. *Pharmaceut Reg Affairs*. 2014; 3: 143.

29. Kane-Gill SL, McCartney LN. The Elusive Quest to Maximize Voluntary Incident Reporting and Optimize Pharmacovigilance: A Matter of the Reporting Mechanisms or More? *Adv Pharmacoepidem Drug Safety*.2012;1: 108.
30. Elkalmi RM, Ahmad Hassali MA, Al-lela QBO, et al.The Teaching of Subjects Related to Pharmacovigilance in Malaysian Pharmacy Undergraduate Programs. *J Pharmacovigilance*.2013; 1: 106.
31. Kaur I, Kalaiselvan V, Kumar R, et al. Effective Reporting by Pharmacist in Pharmacovigilance Programme of India. *Adv Pharmacoepidemiol Drug Saf*. 2015; 4: 197.
32. Sanaa A, Amal AH, Samar R, et al. Awareness and Perception of National Pharmacovigilance Center among Lebanese Medical Staff. *J Pharmacovigilance*. 2016; 4: 199.
33. Yerramilli A, Veerla S, Chintala E, et al. A Pharmacovigilance Study Using Tracer Techniques. *Adv Pharmacoepidemiol Drug Saf*.2014; 3: 165.
34. Dave VS. Current Trends in Pharmacovigilance. *J Pharmacovigilance*.2013; 1: 104.
35. Pournamdar Z, Zare S. Survey of Medication Error Factors from Nurses' Perspective. *Biol Med* .2016; 8: 310.
36. ontanari-Vergallo G. Recent Developments in EU and US Pharmacovigilance Legislation. *J Pharmacovigilance*.2013; 1:105.
37. Kharkar M, Bowalekar S. Extent of Under Reporting of Adverse Drug Reactions (ADRs) in India: Evaluation using Logistic Regression Analysis (LRA) Model. *J Clin Trials*.2014; 4: 155.
38. Yamamoto. The Role of a Pharmacist and Undergraduate Pharmacy Education with Special Reference to the Adverse Drug Reaction Reporting System in Japan. *J Pharmacovigilance*.2013; 1: 113.
39. Chablani L. Pharmacovigilance of Biosimilars. *J Pharmacovigilance*.2013; 1: 107.
40. Yiannakopoulou ECh. Pharmacovigilance for Novel Oral Anticoagulants: Why is It So Crucial?. *J Pharmacovigilance*.2015; 3: 135.
41. Al-Hazmi NN, Naylor IL. A Study of Community Pharmacists' Awareness and Contributions to Adverse Drug Reactions (ADRs) Reporting Systems in the Makkah, Kingdom of Saudi Arabia (KSA).*J Clin Trials*. 2013; 3: 127.
42. Reis CD, Veiga CE, Martins JJ. Pharmacovigilance in Cabo Verde: Measuring the Awareness and Knowledge by Healthcare Professionals. *J Pharmacovigil*. 2015; 3: 177.
43. De Ponti F. New Approaches in Pharmacovigilance in the Pharmacogenomic Era: A Call for Papers. *J Pharmacovigilance*. 2014; 2: 122.
44. Al-Amiry MHA. Pyrazinamide Induced Photosensitivity: A Case Report from Iraq. *J Pharmacovigilance*.2013;1: 103.
45. Tiwari P, Anuradha, D'Cruz S, et al. Adverse Drug Reaction Monitoring in a North Indian Public Teaching Hospital. *J Pharma Care Health Sys*.2016; 3: 164.

46. Mohammad Arif Khan, Krishna Pandey, Krishnamurthi. Pharmacovigilance in India: A Need Indeed. *J Pharmacovigilance*. 2014; 2: 126.
47. Magyar I. The Surveillance of the Adverse Drug Reaction in Romania: Pharmacovigilance in Romania. *Clinic Pharmacol Biopharmaceut S*. 2014; 2: 1.
48. Vallano A, Castañeda PF, Quijada, et al. Hospital Doctors' Views and Concerns about Pharmacovigilance. *J Pharmacovigilance*. 2015; 3: 160.
49. De Ponti F. Global Perspectives in Pharmacovigilance. *J Pharmacovigilance*. 2013; 1: 108.
50. Heidari A. A Pharmacovigilance Study on Linear and Non-Linear Quantitative Structure (Chromatographic) Retention Relationships (QSRR) Models for the Prediction of Retention Time of Anti-Cancer Nano Drugs under Synchrotron Radiations. *J Pharmacovigil*. 2016; 4: 161.
51. Reis CD, Filipe HM, Filipe HM, et al. Pharmacovigilance in Cabo Verde: Measuring the Impact of Pharmacovigilance Educational Campaign on Consumer's Knowledge. *J Pharmacovigil*. 2016; 4: 217.
52. Muhannad RMS, Arwa YA, Omer QBA, et al. Psychometric Evaluation of Physician toward Pharmacovigilance Practice in Iraq. *J Pharmacovigilance*. 2016; 4: 214.
53. Dunning T, Sinclair A. Glucose Lowering Medicines and Older People with Diabetes: The Importance of Comprehensive Assessments and Pharmacovigilance. *J Nurs Care*. 2014; 3: 160.
54. Wertheimer AI. The Curious Path of Pharmacovigilance. *J Pharmacovigilance*. 2013; 1: 109.
55. Soussi Tanani D, Serragui S, Cherrah Y, et al. Signal Management of Disproportionate Reporting in Moroccan Pharmacovigilance: The Lower Limb Edema Induced by Anti-Tuberculosis Drugs. *J Pharmacovigilance*. 2015; 3: 161.
56. Mastroianni PC, Varallo FR, Dagli-Hernandez C Brazilian. Regulation in Pharmacovigilance: A Review. *Pharmaceut Reg Affairs*. 2016; 5: 164.
57. U ZK, Samuel J, Kessler BA, et al. Systematic Approach to Pharmacovigilance beyond the Limits: The Southern Network on Adverse Reactions (SONAR) Projects. *Adv Pharmacoepidemiol Drug Saf*. 2014; 3: 149.
58. Camacho LH, Pai N. Pharmacovigilance of Oncology Biosimilars. *J Pharmacovigilance*. 2015; 3: 1.
59. Gildeeva GN, Yurkov. VI Pharmacovigilance in Russia: Challenges, Prospects and Current State of Affairs. *J Pharmacovigil*. 2016; 4: 206.
60. Ranjan A, Tripathi A, Saurabh A, et al. Signal Detection in Pharmacovigilance: An Application of Subjective Bayesian Inference. *Adv Pharmacoepidemiol Drug Saf*. 2016; 5: 207.
61. Garlapati S, Priyanka S. Cradles of Signals for Pharmacovigilance Process. *J Pharmacovigil*. 2014; 3: 126.

62. Saygi S, Alkas FB, Etikan I, et al. Pharmacovigilance Awareness among the Community Pharmacists and Pharmacy Students in the Turkish Republic of Northern Cyprus. *J Pharmacovigil.* 2016; 4: 204.
63. Raza A, Jamal H. Assessment of Knowledge, Attitudes and Practice among the Medical and Pharmacy Students towards Pharmacovigilance and Adverse Drug Reactions in Abbottabad, Pakistan. *J Pharmacovigilance.* 2015; 3:173.
64. Charfi R, Ben Sassi M, Gaies E, et al. PRES Induced By Cyclosporin with Normal Blood Concentrations in a Bone Marrow Recipient. *J Drug Metab Toxicol.* 2015; 5: 230.
65. Devi S. Use of Informatics in Identification of Adverse Drug Reactions. *J Bioequiv Availab.* 2014; 6: 54.
66. Ozcagli E, Alpertunga B, Tsatsakis AM. Biosimilar Drugs and Pharmacovigilance. *Pharm Anal Acta.* 2015; 6: 416.
67. Garlapati S, Nagandla S. Risk Management Plan Its Importance and Emphasys on Pharmacovigilance Activities. *Adv Pharmacoepidemiol Drug Saf.* 2014; 3: 128.
68. Kaur I, Jindal S, Grover. IS Cutaneous Adverse Drug Reaction with Ofloxacin. *J Pharmacovigilance.* 2014; 2: 144.
69. Necho W, Worku. A Assessment of Knowledge, Attitude and Practice of Health Professionals towards Adverse Drug Reaction Reporting and Factors Associated with Reporting. *J Pharmacovigilance.* 2014; 2: 135.
70. Preda A. Pharmacovigilance in the New Millennium: Challenges, Opportunities and New Directions. *J Pharmacovigilance.* 2013; 1: 106.
71. Limuaco OM, Bautista LMA, Cruz MJC. The Extent of Pharmacovigilance Awareness among Pharmacy Senior Students of Centro Escolar University, Manila, Philippines. *J Pharmacovigilance.* 2014; 2: 121.
72. Muhannad RMS, Arwa YA, Omer QBA, et al. Psychometric Evaluation of Physician toward Pharmacovigilance Practice in Iraq. *J Pharmacovigilance.* 2016; 4: 214.
73. Charfi R, Ben Sassi M, Gaies E, et al. PRES Induced By Cyclosporin with Normal Blood Concentrations in a Bone Marrow Recipient. *J Drug Metab Toxicol.* 2015; 5:230.
74. Magyar I. The Surveillance of the Adverse Drug Reaction in Romania: Pharmacovigilance in Romania. *Clinic Pharmacol Biopharmaceut.* 2014; 2:1.
75. Karampola MI, Emmanouilides CE. Pharmacovigilance for Biosimilars. *J Pharmacovigil.* 2016; 4:196.
76. Preda A. Pharmacovigilance and Beyond. *J Pharmacovigilance.* 2013; 1: 114.
77. Chauhan A, Mittu B. An Outlook to Pharmacovigilance in India. *Pharm Anal Act.* 2015; 6: 179.
78. Huerta-Sánchez OM, Aguilar-Ponce JL, Meneses-García A, et al. Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Biocomparables. *J Pharmacovigil.* 2015; 3:174.

79. Thota P, Vivekanandan K, Prakash J, et al. Weight gain in Association with Insulin Use - An Analysis of Individual Case Safety Reports an Indian Database. *J Pharmacovigilance*. 2014; 2: 119.
80. Mishra H, Kumar V. Pharmacovigilance: Current Scenario in a Tertiary Care Teaching Medical College in North India. *J Pharmacovigilance*.2013; 1: 108.
81. Abjaude SAR, Silva NRd, Marques LAM, et al. Strategies to Stimulate Actions for Pharmacovigilance Decentralization. 2015; 3:165.
82. Obara T, Yamaguchi H, Satoh M, et al. Prevalence, Determinants, and Reasons for the Non-Reporting of Adverse Drug Reactions by Pharmacists in the Miyagi and Hokkaido Regions of Japan. *Adv Pharmacoepidemiol Drug Saf*. 2015; 4:191.
83. Kowalski CJ, Mrdjenovich AJ. Pharmacovigilance Observed: Why Watchful Waiting will Work. *J Clin Diagn Res*. 2015; 3: 114.
84. Abideen PS, Chandrasekaran K, Uma Maheswaran,et al. Implementation of Self Reporting Pharmacovigilance in Anti Tubercular Therapy Using Knowledge Based Approach. *J Pharmacovigilance*.2013; 1: 101.
85. Persaud-Sharma V, Zhou SF. Incorporation of New Technologies into Global Pharmacovigilance. *J Pharmacovigilance*.2013; 1:102.
86. Raza A, Jamal H. Assessment of Knowledge, Attitudes and Practice among the Medical and Pharmacy Students towards Pharmacovigilance and Adverse Drug Reactions in Abbottabad, Pakistan. *J Pharmacovigilance*.2015; 3:173.
87. Napoleone E, Scasserra C. Pharmacovigilance in Pediatric Age: The Role of Family Pediatricians-Medicines for Children Research Network (FP-MCRN). *J Pharmacovigilance*. 2015; 3: 168.
88. Hoang A, Tolentino MS, Tolentino MJ. Macular Supplements Containing Zinc and Vitamin A Should Be Replaced with Meso-Zeaxanthin, Lutein and Zeaxanthin: An Ophthalmic Need for Pharmacovigilance. *J Pharmacovigil*. 2016; 4:195.
89. Toklu HZ, Soyalan M, Gültekin O, et al. The Knowledge and Attitude of the Healthcare Professionals towards Pharmacovigilance and Adverse Drug Reaction Reporting in Northern Cyprus. *J Pharmacovigilance*. 2016; 4:193.
90. Boeker H, Himmighoffen H, Risch M, et al. Attention for Possible Cardiovascular Adverse Effects Under ECT in Association with a Combined Medication of Lithium and Duloxetine. *J Anesth Clin Res*.2016; 7: 651.
91. Brown JD, Hutchison LC, Martin BC. Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. *J Gerontol Geriatr Res*. 2016; 5:321.
92. Elkalmi RM, Al-lela OQ, Jamshed SQ. Motivations and Obstacles for Adverse Drug Reactions Reporting among Healthcare Professionals from the Perspective of Lewin's Force Field Analysis Theory: Analytic Approach. *J Pharmacovigilance*.2014; 2:130.
93. Yamamoto. The Role of a Pharmacist and Undergraduate Pharmacy Education with Special Reference to the Adverse Drug Reaction Reporting System in Japan. *J Pharmacovigilance*. 2013; 1: 113.

94. Gaies E, Jebabli N, Trabelsi S, et al. Methotrexate Side Effects: Review Article. *J Drug Metab Toxicol.*2012; 3:125.
95. Garlapati S. Pharmacoepidemiology – A Lot beyond Pencil and Paper Research. *Adv Pharmacoepidem Drug Safety.*2012; 1:103.
96. Toklu HZ, Soyalan M, Gültekin O, et al. The Knowledge and Attitude of the Healthcare Professionals towards Pharmacovigilance and Adverse Drug Reaction Reporting in Northern Cyprus. *J Pharmacovigilance.*2016; 4:193.
97. Hama R. The Mechanisms of Adverse Reactions to Oseltamivir: Part II. Delayed Type Reactions. *Clin Microbiol.*2015; 4: 224.
98. Bara T, Yamaguchi H, Iida Y, et al. Knowledge of and Perspectives on Pharmacovigilance among Pharmacists in the Miyagi and Hokkaido Regions of Japan. *J Pharmacovigilance.*2016; 4:192.
99. Hang JX. Why does Functional Status Matter for Cost-Related Medication Non-Adherence in the Elderly Population?. *J Gerontol Geriatr Res.* 2016; 5:348.
100. Boeker H, Himmighoffen H, Risch M, et al. Attention for Possible Cardiovascular Adverse Effects Under ECT in Association with a Combined Medication of Lithium and Duloxetine. *J Anesth Clin Res.*2016; 7:651.
101. Amrinder R, Kaur I, Singh J, Kaur T. Monitoring of Cutaneous Adverse Drug Reactions in a Tertiary Care Hospital. *J Pharmacovigilance.*2016; 4: 207.